- Home
- ABSI vs EYPT Comparison
ABSI vs EYPT Comparison
Compare ABSI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- EYPT
- Stock Information
- Founded
- ABSI 2011
- EYPT 1987
- Country
- ABSI United States
- EYPT United States
- Employees
- ABSI 157
- EYPT N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- ABSI Health Care
- EYPT Industrials
- Exchange
- ABSI Nasdaq
- EYPT Nasdaq
- Market Cap
- ABSI 347.0M
- EYPT 390.0M
- IPO Year
- ABSI 2021
- EYPT 2005
- Fundamental
- Price
- ABSI $2.78
- EYPT $8.12
- Analyst Decision
- ABSI Strong Buy
- EYPT Strong Buy
- Analyst Count
- ABSI 5
- EYPT 8
- Target Price
- ABSI $8.40
- EYPT $24.29
- AVG Volume (30 Days)
- ABSI 2.9M
- EYPT 896.8K
- Earning Date
- ABSI 05-13-2025
- EYPT 05-07-2025
- Dividend Yield
- ABSI N/A
- EYPT N/A
- EPS Growth
- ABSI N/A
- EYPT N/A
- EPS
- ABSI N/A
- EYPT N/A
- Revenue
- ABSI $4,815,000.00
- EYPT $56,042,000.00
- Revenue This Year
- ABSI $145.79
- EYPT N/A
- Revenue Next Year
- ABSI $99.29
- EYPT N/A
- P/E Ratio
- ABSI N/A
- EYPT N/A
- Revenue Growth
- ABSI N/A
- EYPT 12.04
- 52 Week Low
- ABSI $2.01
- EYPT $3.91
- 52 Week High
- ABSI $6.33
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- ABSI 48.04
- EYPT 71.92
- Support Level
- ABSI $2.59
- EYPT $5.46
- Resistance Level
- ABSI $2.81
- EYPT $7.44
- Average True Range (ATR)
- ABSI 0.20
- EYPT 0.59
- MACD
- ABSI 0.00
- EYPT 0.21
- Stochastic Oscillator
- ABSI 20.18
- EYPT 95.59
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.